Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

Morning Bell 20 January

Grady Wulff
January 20, 2023

Closing Bell 19 January

Grady Wulff
January 19, 2023

Morning Bell 19 January

Sophia Mavridis
January 19, 2023

Closing Bell 18 January

Grady Wulff
January 18, 2023

Morning Bell 18 January

Grady Wulff
January 18, 2023

Closing Bell 17 January

Grady Wulff
January 17, 2023

Morning Bell 17 January

Sophia Mavridis
January 17, 2023

Closing Bell 16 January

Grady Wulff
January 16, 2023

Morning Bell 16 January

Grady Wulff
January 16, 2023

Thank you and see you in 2023

Grady Wulff
December 20, 2022

Weekly Wrap 16 December

Grady Wulff
December 16, 2022

Morning Bell 16 December

Bell Direct
December 16, 2022